2-Mercaptobenzimidazole is the deuterated analog of 2-benzimidazolethiol, featuring four deuterium substitutions for isotopic labeling studies.

EN25 is a covalent allosteric inhibitor of glutamate-cysteine ligase (GCL), selectively targeting cysteine residue C114 on the GCLM regulatory subunit with an IC50 of 16 μM.

Naphthol AS-BI phosphate sodium salt serves as a specialized chemical substrate for enzymatic detection methods in biochemical research.

AF615 is a potent small-molecule disruptor of the CDT1/Geminin interaction, exhibiting IC50 values of 0.313 μM. This compound demonstrates selective genotoxic effects in cancer cells, including DNA synthesis inhibition, cell cycle arrest, and reduced viability. Binding studies reveal differential affinity for protein variants (Ki = 0.37 μM for Geminin-tCDT1 vs 0.75 μM for Geminin-miniCDT1).

ELOVL6-IN-5 (compound B) is a selective inhibitor targeting ELOVL6, the key regulatory enzyme for elongation of C16 fatty acids. While effectively lowering hepatic fatty acid accumulation in diet-induced obese mice, this inhibitor demonstrated limited efficacy in improving insulin sensitivity, suggesting distinct mechanisms in metabolic regulation.

PD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 μM for μ-Calpain, about 20-fold selectivity over m-calpain.

altering the lifespan of a eukaryotic organism; anti-viral;

inhibitor of flavivirus replication

Protein tyrosine Phosphatase 1B (PTP1B) agonist

neuroprotective effects; altering the lifespan of a eukaryotic organism;

Mycobacterium tuberculosis shikimate kinase inhibitors

useful for preventing or treating obesity, dyslipidemia, fatty liver or diabetes;

Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells.

BMS-195614 is a potent, orally bioavailable RARα antagonist (Ki = 2.5 nM) that modulates multiple signaling pathways. It upregulates Bcl2 expression while suppressing NF-κB, AP-1, and PPAR transactivation. Additionally, it reduces IL-6 and VEGF production, mitigates phototoxic damage from blue light, and exhibits anti-migratory, anti-inflammatory, and anti-angiogenic properties.

AZ3976 is a selective PAI-1 inhibitor that exhibits potent profibrinolytic effects, with IC50 values of 26 μM (chromogenic assay) and 16 μM (plasma clot lysis assay). Unlike conventional inhibitors, it does not target active PAI-1 but instead binds reversibly to the latent form, accelerating the transition of active PAI-1 to its inactive state.

WQ-2101 (WQ2101, PKUMDL-WQ-2101) is a specific, allosteric inhibitor of PHGDH with IC50 of 34.8 uM (WT PHGDH), shows dramatically reduced potenecy for mutants R134A (IC50 =141 uM) and K57AT59A (IC50=128 uM).

ZLD1039 is a novel, orally active EZH2 inhibitor demonstrating high selectivity and potency. It effectively suppresses PRC2 enzymatic activity across wild-type EZH2 (IC50 = 5.6 nM) and mutant forms (Y641F: 15 nM; A677G: 4.0 nM), while exhibiting significant anti-tumor and anti-metastatic effects in breast cancer models.

Novel Inhibitor of Monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA), inhibiting Repair of Interstrand DNA Crosslink, enhancing DNA Double-strand Break, and sensitizing Cancer Cells to Cisplatin.

LY305 is a potent non-steroidal SARM exhibiting high androgen receptor binding affinity (Ki = 2.03 nM) and strong agonist activity in C2C12 cells (EC50 = 0.499 nM), demonstrating its selective modulation capabilities.

corticotropin releasing factor (CRF) antagonist.

Protonstatin-1 is a selective small-molecule inhibitor of PM H+ -ATPase activity that inhibits auxin transport.